Del.icio.us
Google
Yahoo MyWeb
Facebook
Apthera Overview
"Apthera, Inc. was founded in July, 2005 to develop and commercialize a pipeline of clinically-advanced, peptide-based immunotherapies for the adjuvant treatment of HER2-positive cancers. Currently, the Company has products in clinical trials aimed at reducing disease recurrence rates for breast, prostate and pancreatic cancers. Apthera licensed its core intellectual property from The University...More»
"Apthera, Inc. was founded in July, 2005 to develop and commercialize a pipeline of clinically-advanced, peptide-based immunotherapies for the adjuvant treatment of HER2-positive cancers. Currently, the Company has products in clinical trials aimed at reducing disease recurrence rates for breast, prostate and pancreatic cancers. Apthera licensed its core intellectual property from The University of Texas M.D. Anderson Cancer Center (MDACC) in Houston, TX, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) in Rockville, MD.
Apthera recently announced positive Phase II clinical trial results of its lead product, NeuVax™ (E75), for the treatment of breast cancer. NeuVax is an immunotherapy consisting of the E75 peptide mixed with GM-CSF administered intradermally on a monthly basis for 6 months. Planning is underway for a large, international, pivotal Phase III clinical trial of NeuVax."
(Source: Apthera)«Less
Key People
Management
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 04/2008 | Series B | 3.6M | Unknown |
Products
| Name: | NeuVax (E75) |
| Product URL: | http://www.apthera.com/products.php?id=2 |
| Description: | NeuVax is an immunotherapy consisting of the HER2-derived peptide, E75, mixed with GM-CSF and is administered intradermally. NeuVax fights cancer by triggering a "Killer T-cell" immune system response to tumors expressing HER2/neu on their surface. Once NeuVax activates the immune system, Cytotoxic T-Lymphocytes (CTLs) are produced to destroy the target tumor cells while leaving normal, healthy tissue unharmed. Unlike existing monoclonal antibody therapy which requires frequent, ongoing, intravenous (I.V.) infusion, NeuVax can produce continuing activation of the immune system and therapeutic levels of T-cells with a once monthly intradermal (under the skin) dosing schedule that is less expensive and more convenient for both the patient and physician. NeuVax is currently undergoing clinical testing for the treatment of HER2-expressing breast and prostate cancer. NeuVax may also be developed as a treatment for pancreatic, ovarian and non-small cell lung cancers. |
Profile
OpinionsRelated Companies
No related companies were found.
Page Information
02/20/2009 12:11PM by flintstones
User Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | n/a | ||
Apthera on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.
Related Jobs
loading...